Betahistine

Treatment for Meniere's Disease

Typical Dosage: 8-16mg three times daily (24-48mg/day)

Effectiveness
65%
Safety Score
78%
Clinical Trials
2
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
8-16mg three times daily (24-48mg/day)
Time to Effect
2 weeks to 3 months
Treatment Duration
Long-term
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$600
Monitoring:$400
Side Effect Mgmt:$20
Total Annual:$900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$18,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$1,500
Cost per Remission
$3,600
Comparison vs Hydrochlorothiazide + Low Sodium Diet
Cost Difference
+$400/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$900
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$60/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$600/year
Potential OTC Price
$250/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Betahistine Outcomes

for Meniere's Disease

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Remission Rate
+25%
Common Side Effects
Nausea
+8%
Headache
+5%
Indigestion
+4%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
1 active trial recruiting for Betahistine in Meniere's Disease

Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation

NCT06001593RECRUITINGPHASE1, PHASE2
View Study
120 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 18, 2023
Completed Clinical Trials
1 completed trial for Betahistine in Meniere's Disease

Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

NCT00160238COMPLETEDPHASE4
View Study
20 participants
INTERVENTIONAL
Marseille, France
Started: Jan 1, 2003